Polpharma Biologics’ investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®

Posted on by

AMSTERDAM, Feb. 21, 2024 /PRNewswire/ — Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars, today announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamics (PD) comparability of its biosimilar…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.